Alternative methods for the diagnosis of macroprolactinemia: urine prolactin level and serum / urine prolactin ratio
Abstract
Objective:
The aim of this study was to investigate the urine prolactin and serum/urine
prolactin ratio for accuracy diagnosis of macroprolactinemia.
Methods: In
the retrospective cross-sectional analysis, prolactin levels (high or normal)
in the reproductive period of men and women were included in the study.
Polyethylene glycol (PEG) precipitation method was used for the detection of
macroprolactinemia. Then, patients were divided into three groups as
macroprolactinemia, prolactinoma and healthy control group. In patients,
prolactin values in spot urine with simultaneous serum prolactin values were
calculated. The non-parametric Kruskal-Wallis test was used to compare the
groups. The receiver-operating characteristic (ROC) curve was determined to
evaluate the predictive power of serum/urine prolactin ratio.
Results: A
total of 41 patients were included in the study. Female/male:36 (87.8%)/ 5
(12.2%). Urinary prolactin median(minimum-maximum) values were
macroprolactinemia, prolactinoma and control group, respectively;
0.06(0.05-0.10), 0.11(0.02-0.95), 0.08(0.05-0.25) ng/ml. Serum/urine ratio
median (minium-maximum) values were macroprolactinemia, prolactinoma, and control
group, respectively; 633(51-1032), 990(104-9635), 395.5(138-953). When the
groups were compared, the patients with prolactinoma had higher urinary
prolactin levels(p <0.01). Serum/urine prolactin ratio was found to be the
highest in prolactinoma patients and the lowest in the control group and a
significant difference was observed in groups (p <0.01).
ROC
analysis(control-macroprolactin) for serum/urine prolactin ratio (Sensitivity
84.6 specificity 93.7 cut off >549,5 AUC=0.83) p<0.01
Conclusion: Urinary prolactin level and serum/urine prolactin ratio may be used in diagnosis of macroprolactinemia.
Keywords
References
- 1. Horseman ND and Gregerson KA. Prolactin actions. Journal of Molecular Endocrinology. 2014; 52: 95-106.
- 2. Melmed S, Casanueva FF, Hoffman AR, et all. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96: 273-88.
- 3. Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiological Reviews. 2000; 80: 1523–631.
- 4. Molitch ME. Prolactin in human reproduction In: Strauss JF, Barbieri R, eds. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management, 7th edn. Elsevier Saunders, Philadelphia 2014: 45-65.
- 5. Hattori N, Ishihara T, Saiki Y, et all. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol (Oxf). 2010; 73: 792–7.
- 6. Hattori N, Nakayama Y, Kitagawa K, et all. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. Clin Endocrinol (Oxf). 2006; 190: 287-93.
- 7. Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–631.
- 8. Samson SL, Hamrahian AH, Ezzat S. American Association of Clinical Endocrinologists. American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015; 21: 1427–35.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Authors
Mazhar Müslüm Tuna
This is me
0000-0001-5975-7786
Mehmet Güven
This is me
0000-0002-0752-8815
Şadiye Altun Tuzcu
This is me
0000-0003-3326-5358
İbrahim Kaplan
This is me
0000-0003-2813-1064
Zeki Akkuş
This is me
0000-0002-6161-3666
Alpaslan Kemal Tuzcu
This is me
0000-0002-1814-9773
Publication Date
March 3, 2019
Submission Date
November 2, 2018
Acceptance Date
December 14, 2018
Published in Issue
Year 2019 Volume: 46 Number: 1